Yerba Mate trials recruiting now

1 registration that name yerba Mate as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.

Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.

Filter 1 registration

Status

All 1 registrations

RecruitingNCT06896175

Effect of Ilex Paraguariensis Harvest Time and Consumption Method of Processed Yerba Mate on the Lipid Profile

  • No phase
  • Universidad Nacional de Caaguazu
  • About 198 people
  • Started Feb 1, 2026

In plain words A study of yerba Mate in people 18 to 60, run by Universidad Nacional de Caaguazu. It plans to enroll about 198 people at 1 site, none in the US.

Who it lists and where

Who the trial lists, as registered

Lists people 18 to 60; healthy volunteers accepted. Conditions: Lipid Metabolism Disorders.

  • Individuals of both sexes, between 18 and 60 years of age, residing in the country, who consume prepared yerba mate.
  • Consumers of mate or tereré and mate/terere who agree to consume the yerba mate samples provided by the research team, which will be masked from laboratory analysis.
  • Two weeks of abstinence from consuming prepared yerba mate, either as mate or tereré, prior to randomization for the trial.
  • Consume exclusively prepared yerba mate in the prescribed manner (quantity of yerba, frequency of consumption, and sips), either in its mate or tereré form independently, and for those who consume both forms daily.

2 more inclusion criteria and the exclusion criteria are on the listing.

What it tests, as registered

Yerba mate consumption (Ilex paraguayensis) A; Yerba mate comsuption (ilex paraguayencis) B

Registered summary

Introduction: This project studies the impact of Ilex paraguariensis harvest time, commonly known as yerba mate, and its consumption mode (mate, tereré, and mate/terere) on the lipid profile of consumers in the Department of Caaguazú, Paraguay. Yerba mate is rich in bioactive compounds such as polyphenols, xanthines, and saponins. There are no clinical trials conducted in Paraguay with our Ilex paraguariensis plantations that have analyzed the influence of harvest time on the yerba mate production process and the infusion mode, in relation to its effect on dyslipidemias. The full summary is on the listing.

Where, as registered

No US site; Paraguay (1).

ClinicalTrials.gov lists 9 open registrations for this search, including ones where yerba Mate is not a study arm or that are past the 1 we keep. Search them on ClinicalTrials.gov (opens in new tab).

Educational only. Not medical advice. Some links earn us a commission: kymatahealth.com/affiliate-disclosure.